Valuation Gilead Sciences, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			After hours 01:00:00
129.83 ^USD	-3.72%		130.70	+0.67%

07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	161,193	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	5.85%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	170,653	161,097	151,100
Change	-	6.74%	-6.21%	11.1%	28.63%	0.63%	-5.6%	-6.21%
P/E	14.7x	23.6x	18x	243x	18.1x	-46x	16.9x	15.6x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.12x	6.45x	5.26x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.89x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.29x	4.98x	4.72x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.6x	4.98x	4.42x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	31.1x	9.04x	8.32x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	61.8x	10.4x	9.1x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	168x	12.2x	10.8x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.6%	8.21%	9.27%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.246	3.362	3.099
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.5%	2.59%	2.39%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.821	7.701	8.335
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-115%	43.7%	37.2%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,470	32,377	34,167
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,484	17,828	18,171
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,760	15,503	16,606
Net income ¹	6,225	4,592	5,665	480	8,510	-3,373	9,548	10,218
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,460	-96.43	-10,093
Reference price ²	72.61	85.85	81.01	92.37	122.74	129.83	129.83	129.83
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,241,570	-	-
Announcement Date	01/02/22	02/02/23	06/02/24	11/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
GILEAD SCIENCES, INC.	-46.02x	5.6x	31.12x	2.5%	161B
ELI LILLY AND COMPANY	34.92x	12.63x	25.81x	0.57%	1,060B
JOHNSON & JOHNSON	27.42x	6.3x	17.1x	2.08%	619B
ABBVIE INC.	30x	7.34x	15.02x	2.76%	438B
ROCHE HOLDING AG	17.98x	4.45x	11.01x	2.97%	333B
NOVARTIS AG	21.52x	5.52x	13.36x	2.86%	282B
ASTRAZENECA PLC	21.56x	4.53x	12.65x	1.94%	267B
NOVO NORDISK A/S	14.17x	5.3x	10.9x	3.52%	218B
AMGEN INC.	23.77x	6.31x	11.12x	2.78%	196B
PFIZER INC.	12.29x	3.03x	7.56x	7.14%	138B
Average	15.76x	6.10x	15.57x	2.91%	371.17B
Weighted average by Cap.	23.43x	7.67x	17.77x	2.19%